Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab for reimbursement as a treatment option for the maintenance treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer in adult patients, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.
This is written in the approval document as:
Pertuzumab in combination with trastuzumab for the maintenance treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HSE (1) | HER2-positive | Invasive Breast Carcinoma | Pertuzumab, Trastuzumab |